메뉴 건너뛰기




Volumn 41, Issue 1, 2014, Pages 57-68

Radiation therapy as a backbone of treatment of locally advanced non-small cell lung cancer

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; RADIOTHERAPY;

EID: 84894440372     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2013.12.012     Document Type: Article
Times cited : (17)

References (80)
  • 2
    • 17144436630 scopus 로고    scopus 로고
    • Combined modality therapy for non-small cell lung cancer, past, present, and future
    • D.W. Kim, and H. Choy Combined modality therapy for non-small cell lung cancer, past, present, and future Lung Cancer 42 2003 S35 S40
    • (2003) Lung Cancer , vol.42
    • Kim, D.W.1    Choy, H.2
  • 3
    • 84866904966 scopus 로고    scopus 로고
    • Personalized combined modality therapy for locally advanced non-small cell lung cancer
    • D.N. Kim, T.K. Nam, K.S. Choe, and H. Choy Personalized combined modality therapy for locally advanced non-small cell lung cancer Cancer Res Treat 44 2012 74 84
    • (2012) Cancer Res Treat , vol.44 , pp. 74-84
    • Kim, D.N.1    Nam, T.K.2    Choe, K.S.3    Choy, H.4
  • 4
    • 30544441331 scopus 로고    scopus 로고
    • Prognostic factors for survival in stage III non-small-cell lung cancer treated with definitive radiation therapy: Impact of tumor volume
    • K. Basaki, Y. Abe, M. Aoki, H. Kondo, Y. Hatayama, and S. Nakaji Prognostic factors for survival in stage III non-small-cell lung cancer treated with definitive radiation therapy: impact of tumor volume Int J Radiat Oncol Biol Phys 64 2006 449 454
    • (2006) Int J Radiat Oncol Biol Phys , vol.64 , pp. 449-454
    • Basaki, K.1    Abe, Y.2    Aoki, M.3    Kondo, H.4    Hatayama, Y.5    Nakaji, S.6
  • 5
    • 0029778934 scopus 로고    scopus 로고
    • Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial
    • R.O. Dillman, J. Herndon, S.L. Seagren, W.L. Eaton Jr, and M.R. Green Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial J Natl Cancer Inst 88 1996 1210 1215
    • (1996) J Natl Cancer Inst , vol.88 , pp. 1210-1215
    • Dillman, R.O.1    Herndon, J.2    Seagren, S.L.3    Eaton, Jr.W.L.4    Green, M.R.5
  • 6
    • 0025307174 scopus 로고
    • Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer
    • D.H. Johnson, L.H. Einhorn, and A. Bartolucci et al. Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer Ann Intern Med 113 1990 33 38
    • (1990) Ann Intern Med , vol.113 , pp. 33-38
    • Johnson, D.H.1    Einhorn, L.H.2    Bartolucci, A.3
  • 7
    • 0028909219 scopus 로고
    • Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer
    • W.T. Sause, C. Scott, and S. Taylor et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer J Natl Cancer Inst 87 1995 198 205
    • (1995) J Natl Cancer Inst , vol.87 , pp. 198-205
    • Sause, W.T.1    Scott, C.2    Taylor, S.3
  • 10
    • 34249988209 scopus 로고    scopus 로고
    • A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer
    • S. Yuan, X. Sun, and M. Li et al. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer Am J Clin Oncol Cancer Clin Trials 30 2007 239 244
    • (2007) Am J Clin Oncol Cancer Clin Trials , vol.30 , pp. 239-244
    • Yuan, S.1    Sun, X.2    Li, M.3
  • 11
    • 0346238665 scopus 로고    scopus 로고
    • Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer
    • T. Le Chevalier, R. Arriagada, and C. Le Pechoux et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer N Engl J Med 350 2004 351 360
    • (2004) N Engl J Med , vol.350 , pp. 351-360
    • Le Chevalier, T.1    Arriagada, R.2    Le Pechoux, C.3
  • 12
    • 77951804823 scopus 로고    scopus 로고
    • A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages i to III non-small-cell lung cancer: Phase i results of RTOG 0117
    • J.D. Bradley, J. Moughan, and M.V. Graham et al. A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117 Int J Radiat Oncol Biol Phys 77 2010 367 372
    • (2010) Int J Radiat Oncol Biol Phys , vol.77 , pp. 367-372
    • Bradley, J.D.1    Moughan, J.2    Graham, M.V.3
  • 13
    • 0036803119 scopus 로고    scopus 로고
    • High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: Technical issues and results of a phase I/II trial
    • J.G. Rosenman, J.S. Halle, and M.A. Socinski et al. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial Int J Radiat Oncol Biol Phys 54 2002 348 356
    • (2002) Int J Radiat Oncol Biol Phys , vol.54 , pp. 348-356
    • Rosenman, J.G.1    Halle, J.S.2    Socinski, M.A.3
  • 14
    • 33745185115 scopus 로고    scopus 로고
    • Results of a phase i trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer
    • S.E. Schild, W.L. McGinnis, and D. Graham et al. Results of a phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer Int J Radiat Oncol Biol Phys 65 2006 1106 1111
    • (2006) Int J Radiat Oncol Biol Phys , vol.65 , pp. 1106-1111
    • Schild, S.E.1    McGinnis, W.L.2    Graham, D.3
  • 15
    • 0036499649 scopus 로고    scopus 로고
    • Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer
    • M.A. Socinski, M.J. Schell, and A. Peterman et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer J Clin Oncol 20 2002 1335 1343
    • (2002) J Clin Oncol , vol.20 , pp. 1335-1343
    • Socinski, M.A.1    Schell, M.J.2    Peterman, A.3
  • 16
    • 84858792325 scopus 로고    scopus 로고
    • Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma. A Radiation Therapy Oncology Group analysis
    • M. Machtay, R. Paulus, and J. Moughan et al. Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma. A Radiation Therapy Oncology Group analysis J Thorac Oncol 7 2012 716 722
    • (2012) J Thorac Oncol , vol.7 , pp. 716-722
    • Machtay, M.1    Paulus, R.2    Moughan, J.3
  • 17
    • 84894452942 scopus 로고    scopus 로고
    • A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy +/- cetuximab for stage IIIa/IIIb non-small cell lung cancer: Preliminary findings on radiation dose in RTOG 0617 (late-breaking abstract 2)
    • Miami, FL
    • Bradley JPR, Komaki R, et al. A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy +/- cetuximab for stage IIIa/IIIb non-small cell lung cancer: preliminary findings on radiation dose in RTOG 0617 (late-breaking abstract 2). 53rd Annual Meeting of the American Society of Radiation Oncology; 2011; Miami, FL.
    • (2011) 53rd Annual Meeting of the American Society of Radiation Oncology
    • Jpr, B.1    Komaki, R.2
  • 18
    • 80054072961 scopus 로고    scopus 로고
    • Sequential v concurrent chemoradiation for stage III non-small cell lung cancer: Randomized phase III trial RTOG 9410
    • W.J. Curran Jr, R. Paulus, and C.J. Langer et al. Sequential v concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410 J Natl Cancer Inst 103 2011 1452 1460
    • (2011) J Natl Cancer Inst , vol.103 , pp. 1452-1460
    • Curran, Jr.W.J.1    Paulus, R.2    Langer, C.J.3
  • 19
    • 0036805582 scopus 로고    scopus 로고
    • Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in stage III non-small-cell lung cancer
    • S.E. Schild, P.J. Stella, and S.M. Geyer et al. Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in stage III non-small-cell lung cancer Int J Radiat Oncol Biol Phys 54 2002 370 378
    • (2002) Int J Radiat Oncol Biol Phys , vol.54 , pp. 370-378
    • Schild, S.E.1    Stella, P.J.2    Geyer, S.M.3
  • 20
    • 0030737527 scopus 로고    scopus 로고
    • Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: A randomised multicentre trial
    • M. Saunders, S. Dische, A. Barrett, A. Harvey, D. Gibson, and M. Parmar Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial Lancet 350 1997 161 165
    • (1997) Lancet , vol.350 , pp. 161-165
    • Saunders, M.1    Dische, S.2    Barrett, A.3    Harvey, A.4    Gibson, D.5    Parmar, M.6
  • 21
    • 20544435485 scopus 로고    scopus 로고
    • Phase III study of the eastern cooperative oncology group (ECOG 2597): Induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer
    • C.P. Belani, W. Wang, and D.H. Johnson et al. Phase III study of the eastern cooperative oncology group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer J Clin Oncol 23 2005 3760 3767
    • (2005) J Clin Oncol , vol.23 , pp. 3760-3767
    • Belani, C.P.1    Wang, W.2    Johnson, D.H.3
  • 22
    • 84864564911 scopus 로고    scopus 로고
    • Hyperfractionated or accelerated radiotherapy in lung cancer: An individual patient data meta-analysis
    • A. Mauguen, C. Le Pechoux, and M.I. Saunders et al. Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis J Clin Oncol 30 2012 2788 2797
    • (2012) J Clin Oncol , vol.30 , pp. 2788-2797
    • Mauguen, A.1    Le Pechoux, C.2    Saunders, M.I.3
  • 23
    • 67651124771 scopus 로고    scopus 로고
    • A phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable stage III non-small-cell lung cancer: Results of Korean Radiation Oncology Group 0301 study
    • K.H. Cho, S.J. Ahn, and H.R. Pyo et al. A phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study Int J Radiat Oncol Biol Phys 74 2009 1397 1404
    • (2009) Int J Radiat Oncol Biol Phys , vol.74 , pp. 1397-1404
    • Cho, K.H.1    Ahn, S.J.2    Pyo, H.R.3
  • 24
    • 84894505501 scopus 로고    scopus 로고
    • Soccar: Sequential or concurrent chemotherapy and hypofractionated accelerated radiotherapy in inoperable stage III NSCLC
    • J. Maguire, N. O'Rourke, and C. Peedell et al. Soccar: sequential or concurrent chemotherapy and hypofractionated accelerated radiotherapy in inoperable stage III NSCLC J Thorac Oncol 6 2011 S1561 S1562
    • (2011) J Thorac Oncol , vol.6
    • Maguire, J.1    O'Rourke, N.2    Peedell, C.3
  • 25
    • 0029113383 scopus 로고
    • Stage i nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence
    • D.H. Harpole Jr., J.E. Herndon 2nd, W.G. Young Jr., W.G. Wolfe, and D.C. Sabiston Jr Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence Cancer 76 1995 787 796
    • (1995) Cancer , vol.76 , pp. 787-796
    • Harpole, Jr.D.H.1    Herndon II, J.E.2    Young, Jr.W.G.3    Wolfe, W.G.4    Sabiston, Jr.D.C.5
  • 26
    • 33747852920 scopus 로고    scopus 로고
    • Local recurrence following initial resection of NSCLC: Salvage is possible with radiation therapy
    • C.R. Kelsey, R.W. Clough, and L.B. Marks Local recurrence following initial resection of NSCLC: salvage is possible with radiation therapy Cancer J 12 2006 283 288
    • (2006) Cancer J , vol.12 , pp. 283-288
    • Kelsey, C.R.1    Clough, R.W.2    Marks, L.B.3
  • 27
    • 0033993435 scopus 로고    scopus 로고
    • Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer - Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group
    • W. Sause, P. Kolesar, and S. Taylor et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer - Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group Chest 117 2000 358 364
    • (2000) Chest , vol.117 , pp. 358-364
    • Sause, W.1    Kolesar, P.2    Taylor, S.3
  • 28
    • 4244045520 scopus 로고    scopus 로고
    • Non-small Cell Lung Cancer Collaborative Group
    • Chemotherapy for non-small cell lung cancer
    • Chemotherapy for non-small cell lung cancer Non-small Cell Lung Cancer Collaborative Group Cochrane Database Syst Rev 2000 CD002139
    • (2000) Cochrane Database Syst Rev , pp. 002139
  • 29
    • 34247212838 scopus 로고    scopus 로고
    • Management of unresected stage III non-small cell lung cancer: A systematic review
    • Lung Cancer Disease Site Group of Cancer Care Ontario's Program in evidence-based cancer
    • G. Okawara, J.A. Mackay, W.K. Evans, Y.C. Ung Lung Cancer Disease Site Group of Cancer Care Ontario's Program in evidence-based cancer Management of unresected stage III non-small cell lung cancer: a systematic review J Thorac Oncol 1 2006 377 393
    • (2006) J Thorac Oncol , vol.1 , pp. 377-393
    • Okawara, G.1    Mackay, J.A.2    Evans, W.K.3    Ung, Y.C.4
  • 30
    • 0032858243 scopus 로고    scopus 로고
    • Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer
    • K. Furuse, M. Fukuoka, and M. Kawahara et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer J Clin Oncol 17 1999 2692 2699
    • (1999) J Clin Oncol , vol.17 , pp. 2692-2699
    • Furuse, K.1    Fukuoka, M.2    Kawahara, M.3
  • 31
    • 57449090435 scopus 로고    scopus 로고
    • Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: The Hoosier Oncology Group and US Oncology
    • N. Hanna, M. Neubauer, and C. Yiannoutsos et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and US Oncology J Clin Oncol 26 2008 5755 5760
    • (2008) J Clin Oncol , vol.26 , pp. 5755-5760
    • Hanna, N.1    Neubauer, M.2    Yiannoutsos, C.3
  • 32
    • 34248651350 scopus 로고    scopus 로고
    • Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B
    • E.E. Vokes, J.E. Herndon II, and M.J. Kelley et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B J Clin Oncol 25 2007 1698 1704
    • (2007) J Clin Oncol , vol.25 , pp. 1698-1704
    • Vokes, E.E.1    Herndon, I.I.J.E.2    Kelley, M.J.3
  • 33
    • 77957287051 scopus 로고    scopus 로고
    • Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105
    • N. Yamamoto, K. Nakagawa, and Y. Nishimura et al. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105 J Clin Oncol 28 2010 3739 3745
    • (2010) J Clin Oncol , vol.28 , pp. 3739-3745
    • Yamamoto, N.1    Nakagawa, K.2    Nishimura, Y.3
  • 34
    • 84862802175 scopus 로고    scopus 로고
    • Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer
    • L. Wang, S. Wu, and G. Ou et al. Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer Lung Cancer 77 2012 89 96
    • (2012) Lung Cancer , vol.77 , pp. 89-96
    • Wang, L.1    Wu, S.2    Ou, G.3
  • 35
    • 70350225538 scopus 로고    scopus 로고
    • Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase 3 study
    • T. Ciuleanu, T. Brodowicz, and C. Zielinski et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study Lancet 374 2009 1432 1440
    • (2009) Lancet , vol.374 , pp. 1432-1440
    • Ciuleanu, T.1    Brodowicz, T.2    Zielinski, C.3
  • 36
    • 64049115311 scopus 로고    scopus 로고
    • The differential efficacy of pemetrexed according to NSCLC histology: A review of two phase III studies
    • G. Scagliotti, N. Hanna, and F. Fossella et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies Oncologist 14 2009 253 263
    • (2009) Oncologist , vol.14 , pp. 253-263
    • Scagliotti, G.1    Hanna, N.2    Fossella, F.3
  • 37
    • 84875944153 scopus 로고    scopus 로고
    • New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer
    • J.K. Salama, and E.E. Vokes New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer J Clin Oncol 31 2013 1029 1038
    • (2013) J Clin Oncol , vol.31 , pp. 1029-1038
    • Salama, J.K.1    Vokes, E.E.2
  • 38
    • 24944542868 scopus 로고    scopus 로고
    • Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: A randomized phase II locally advanced multi-modality protocol
    • C.P. Belani, H. Choy, and P. Bonomi et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol J Clin Oncol 23 2005 5883 5891
    • (2005) J Clin Oncol , vol.23 , pp. 5883-5891
    • Belani, C.P.1    Choy, H.2    Bonomi, P.3
  • 39
    • 0038688474 scopus 로고    scopus 로고
    • Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: Phase II Southwest Oncology Group Study S9504
    • D.R. Gandara, K. Chansky, and K.S. Albain et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504 J Clin Oncol 21 2003 2004 2010
    • (2003) J Clin Oncol , vol.21 , pp. 2004-2010
    • Gandara, D.R.1    Chansky, K.2    Albain, K.S.3
  • 40
    • 84894422219 scopus 로고    scopus 로고
    • GILT phase III study: Concomitant radiotherapy (RT) with oral vinorelbine (NVBo) plus cisplatin (P) followed by consolidation (C) with NVBo+P plus BSC or BSC alone in stage (st) III NSCLC
    • R.M. Huber, W. Engel-Riedel, and J. Kollmeier et al. GILT phase III study: concomitant radiotherapy (RT) with oral vinorelbine (NVBo) plus cisplatin (P) followed by consolidation (C) with NVBo+P plus BSC or BSC alone in stage (st) III NSCLC Onkologie 35 2012 167 168
    • (2012) Onkologie , vol.35 , pp. 167-168
    • Huber, R.M.1    Engel-Riedel, W.2    Kollmeier, J.3
  • 41
    • 34250832918 scopus 로고    scopus 로고
    • Effect of paclitaxel-carboplatin (PC) consolidation chemotherapy after weekly PC concurrent chemo-radiotherapy (CCR) for patients with locally advanced non-small cell lung cancer (LA-NSCLC): 3-year definitive results of the B001-phase III GERCOR-study
    • 392S-S
    • P. Colin, N. Jovenin, and G. Ganem et al. Effect of paclitaxel- carboplatin (PC) consolidation chemotherapy after weekly PC concurrent chemo-radiotherapy (CCR) for patients with locally advanced non-small cell lung cancer (LA-NSCLC): 3-year definitive results of the B001-phase III GERCOR-study J Clin Oncol 24 2006 392S-S
    • (2006) J Clin Oncol , vol.24
    • Colin, P.1    Jovenin, N.2    Ganem, G.3
  • 43
    • 16544374983 scopus 로고    scopus 로고
    • Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy
    • P. Huguenin, K.T. Beer, and A. Allal et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy J Clin Oncol 22 2004 4665 4673
    • (2004) J Clin Oncol , vol.22 , pp. 4665-4673
    • Huguenin, P.1    Beer, K.T.2    Allal, A.3
  • 45
    • 0031054990 scopus 로고    scopus 로고
    • Epidermal growth factor receptor family and chemosensitization
    • J. Mendelsohn, and Z. Fan Epidermal growth factor receptor family and chemosensitization J Natl Cancer Inst 89 1997 341 343
    • (1997) J Natl Cancer Inst , vol.89 , pp. 341-343
    • Mendelsohn, J.1    Fan, Z.2
  • 47
    • 32144433159 scopus 로고    scopus 로고
    • Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
    • J.A. Bonner, P.M. Harari, and J. Giralt et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 2006 567 578
    • (2006) N Engl J Med , vol.354 , pp. 567-578
    • Bonner, J.A.1    Harari, P.M.2    Giralt, J.3
  • 48
    • 79959195283 scopus 로고    scopus 로고
    • Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324
    • G.R. Blumenschein Jr, R. Paulus, and W.J. Curran et al. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324 J Clin Oncol 29 2011 2312 2318
    • (2011) J Clin Oncol , vol.29 , pp. 2312-2318
    • Blumenschein, Jr.G.R.1    Paulus, R.2    Curran, W.J.3
  • 49
    • 80051742422 scopus 로고    scopus 로고
    • Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B Trial 30407
    • R. Govindan, J. Bogart, and T. Stinchcombe et al. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B Trial 30407 J Clin Oncol 29 2011 3120 3125
    • (2011) J Clin Oncol , vol.29 , pp. 3120-3125
    • Govindan, R.1    Bogart, J.2    Stinchcombe, T.3
  • 50
    • 34748831698 scopus 로고    scopus 로고
    • Biology of interactions: Antiepidermal growth factor receptor agents
    • P.M. Harari, G.W. Allen, and J.A. Bonner Biology of interactions: antiepidermal growth factor receptor agents J Clin Oncol 25 2007 4057 4065
    • (2007) J Clin Oncol , vol.25 , pp. 4057-4065
    • Harari, P.M.1    Allen, G.W.2    Bonner, J.A.3
  • 51
    • 0012381722 scopus 로고    scopus 로고
    • Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer
    • M. Fukuoka, S. Yano, and G. Giaccone et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer J Clin Oncol 21 2003 2237 2246
    • (2003) J Clin Oncol , vol.21 , pp. 2237-2246
    • Fukuoka, M.1    Yano, S.2    Giaccone, G.3
  • 52
    • 0142055937 scopus 로고    scopus 로고
    • Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - A randomized trial
    • M.G. Kris, R.B. Natale, and R.S. Herbst et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - a randomized trial JAMA 290 2003 2149 2158
    • (2003) JAMA , vol.290 , pp. 2149-2158
    • Kris, M.G.1    Natale, R.B.2    Herbst, R.S.3
  • 53
    • 1542503746 scopus 로고    scopus 로고
    • Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT1
    • G. Giaccone, R.S. Herbst, and C. Manegold et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT1 J Clin Oncol 22 2004 777 784
    • (2004) J Clin Oncol , vol.22 , pp. 777-784
    • Giaccone, G.1    Herbst, R.S.2    Manegold, C.3
  • 54
    • 1542713370 scopus 로고    scopus 로고
    • Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2
    • R.S. Herbst, G. Giaccone, J.H. Schiller, R.B. Natale, and V. Miller Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2 J Clin Oncol 22 2004 785 794
    • (2004) J Clin Oncol , vol.22 , pp. 785-794
    • Herbst, R.S.1    Giaccone, G.2    Schiller, J.H.3    Natale, R.B.4    Miller, V.5
  • 55
    • 2342471392 scopus 로고    scopus 로고
    • Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    • T.J. Lynch, D.W. Bell, and R. Sordella et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
    • (2004) N Engl J Med , vol.350 , pp. 2129-2139
    • Lynch, T.J.1    Bell, D.W.2    Sordella, R.3
  • 56
    • 2342624080 scopus 로고    scopus 로고
    • EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy
    • J.G. Paez, P.A. Janne, and J.C. Lee et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
    • (2004) Science , vol.304 , pp. 1497-1500
    • Paez, J.G.1    Janne, P.A.2    Lee, J.C.3
  • 57
    • 45149102984 scopus 로고    scopus 로고
    • Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023
    • K. Kelly, K. Chansky, and L.E. Gaspar et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023 J Clin Oncol 26 2008 2450 2456
    • (2008) J Clin Oncol , vol.26 , pp. 2450-2456
    • Kelly, K.1    Chansky, K.2    Gaspar, L.E.3
  • 58
    • 77956267159 scopus 로고    scopus 로고
    • Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis Cancer and Leukemia Group B (CALEB) 30106, a CALGB-stratified phase II trial
    • N. Ready, P.A. Jaenne, and J. Bogart et al. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis Cancer and Leukemia Group B (CALEB) 30106, a CALGB-stratified phase II trial J Thorac Oncol 5 2010 1382 1390
    • (2010) J Thorac Oncol , vol.5 , pp. 1382-1390
    • Ready, N.1    Jaenne, P.A.2    Bogart, J.3
  • 59
    • 58149132003 scopus 로고    scopus 로고
    • Phase i trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer
    • N.W. Choong, A.M. Mauer, and D.J. Haraf et al. Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer J Thorac Oncol 3 2008 1003 1011
    • (2008) J Thorac Oncol , vol.3 , pp. 1003-1011
    • Choong, N.W.1    Mauer, A.M.2    Haraf, D.J.3
  • 60
    • 34248140107 scopus 로고    scopus 로고
    • Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial
    • U. Gatzemeier, A. Pluzanska, and A. Szczesna et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial J Clin Oncol 25 2007 1545 1552
    • (2007) J Clin Oncol , vol.25 , pp. 1545-1552
    • Gatzemeier, U.1    Pluzanska, A.2    Szczesna, A.3
  • 61
    • 24944440830 scopus 로고    scopus 로고
    • TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
    • R.S. Herbst, D. Prager, and R. Hermann et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 23 2005 5892 5899
    • (2005) J Clin Oncol , vol.23 , pp. 5892-5899
    • Herbst, R.S.1    Prager, D.2    Hermann, R.3
  • 62
    • 22044445517 scopus 로고    scopus 로고
    • Erlotinib in previously treated non-small-cell lung cancer
    • F.A. Shepherd, J.R. Pereira, and T. Ciuleanu et al. Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132
    • (2005) N Engl J Med , vol.353 , pp. 123-132
    • Shepherd, F.A.1    Pereira, J.R.2    Ciuleanu, T.3
  • 63
    • 84863892117 scopus 로고    scopus 로고
    • Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial
    • P.A. Janne, X. Wang, and M.A. Socinski et al. Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial J Clin Oncol 30 2012 2063 2069
    • (2012) J Clin Oncol , vol.30 , pp. 2063-2069
    • Janne, P.A.1    Wang, X.2    Socinski, M.A.3
  • 64
    • 18244419396 scopus 로고    scopus 로고
    • Combined effects of angiostatin and ionizing radiation in antitumour therapy
    • H.J. Mauceri, N.N. Hanna, and M.A. Beckett et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy Nature 394 1998 287 291
    • (1998) Nature , vol.394 , pp. 287-291
    • Mauceri, H.J.1    Hanna, N.N.2    Beckett, M.A.3
  • 65
    • 11844254414 scopus 로고    scopus 로고
    • Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
    • R.K. Jain Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307 2005 58 62
    • (2005) Science , vol.307 , pp. 58-62
    • Jain, R.K.1
  • 66
    • 11144354392 scopus 로고    scopus 로고
    • Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
    • C.G. Willett, Y. Boucher, and E. di Tomaso et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nature Med 10 2004 145 147
    • (2004) Nature Med , vol.10 , pp. 145-147
    • Willett, C.G.1    Boucher, Y.2    Di Tomaso, E.3
  • 67
    • 73949149605 scopus 로고    scopus 로고
    • Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab
    • D.R. Spigel, J.D. Hainsworth, and D.A. Yardley et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab J Clin Oncol 28 2010 43 48
    • (2010) J Clin Oncol , vol.28 , pp. 43-48
    • Spigel, D.R.1    Hainsworth, J.D.2    Yardley, D.A.3
  • 68
    • 0032708238 scopus 로고    scopus 로고
    • Thalidomide - A revival story
    • N. Raje, and K. Anderson Thalidomide - a revival story N Engl J Med 341 1999 1606 1609
    • (1999) N Engl J Med , vol.341 , pp. 1606-1609
    • Raje, N.1    Anderson, K.2
  • 69
    • 84863116718 scopus 로고    scopus 로고
    • Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: The ECOG 3598 study
    • T. Hoang, S.E. Dahlberg, and J.H. Schiller et al. Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study J Clin Oncol 30 2012 616 622
    • (2012) J Clin Oncol , vol.30 , pp. 616-622
    • Hoang, T.1    Dahlberg, S.E.2    Schiller, J.H.3
  • 70
    • 34547638047 scopus 로고    scopus 로고
    • Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
    • 561-U3
    • M. Soda, Y.L. Choi, and M. Enomoto et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 2007 561-U3
    • (2007) Nature , vol.448
    • Soda, M.1    Choi, Y.L.2    Enomoto, M.3
  • 71
    • 82555205501 scopus 로고    scopus 로고
    • New strategies for treatment of ALK-rearranged non-small cell lung cancers
    • T. Sasaki, and P.A. Jaenne New strategies for treatment of ALK-rearranged non-small cell lung cancers Clin Cancer Res 17 2011 7213 7218
    • (2011) Clin Cancer Res , vol.17 , pp. 7213-7218
    • Sasaki, T.1    Jaenne, P.A.2
  • 72
    • 26844536978 scopus 로고    scopus 로고
    • Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    • E.H. Romond, E.A. Perez, and J. Bryant et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 2005 1673 1684
    • (2005) N Engl J Med , vol.353 , pp. 1673-1684
    • Romond, E.H.1    Perez, E.A.2    Bryant, J.3
  • 74
    • 20344362646 scopus 로고    scopus 로고
    • Importance of local control in an era of systemic therapy
    • S. Hellman, and R.R. Weichselbaum Importance of local control in an era of systemic therapy Nat Clin Pract Oncol 2 2005 60 61
    • (2005) Nat Clin Pract Oncol , vol.2 , pp. 60-61
    • Hellman, S.1    Weichselbaum, R.R.2
  • 75
    • 84876510572 scopus 로고    scopus 로고
    • A call for the aggressive treatment of oligometastatic and oligo-recurrent non-small cell lung cancer
    • P.R. Patel, D.S. Yoo, Y. Niibe, J.J. Urbanic, and J.K. Salama A call for the aggressive treatment of oligometastatic and oligo-recurrent non-small cell lung cancer Pulm Med 2012 2012 480961
    • (2012) Pulm Med , vol.2012 , pp. 480961
    • Patel, P.R.1    Yoo, D.S.2    Niibe, Y.3    Urbanic, J.J.4    Salama, J.K.5
  • 76
    • 84876094979 scopus 로고    scopus 로고
    • Extracranial oligometastases: A subset of metastases curable with stereotactic radiotherapy
    • K.S. Corbin, S. Hellman, and R.R. Weichselbaum Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy J Clin Oncol 31 2013 1384 1390
    • (2013) J Clin Oncol , vol.31 , pp. 1384-1390
    • Corbin, K.S.1    Hellman, S.2    Weichselbaum, R.R.3
  • 77
    • 16644368518 scopus 로고    scopus 로고
    • Analysis of further disease progression in metastatic non-small cell lung cancer: Implications for locoregional treatment
    • N. Mehta, A.M. Mauer, and S. Hellman et al. Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment Int J Oncol 25 2004 1677 1683
    • (2004) Int J Oncol , vol.25 , pp. 1677-1683
    • Mehta, N.1    Mauer, A.M.2    Hellman, S.3
  • 78
    • 65549125983 scopus 로고    scopus 로고
    • Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis
    • K.E. Rusthoven, S.F. Hammerman, B.D. Kavanagh, M.J. Birtwhistle, M Stares, and D.R Camidge Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis Acta Oncol 48 2009 578 583
    • (2009) Acta Oncol , vol.48 , pp. 578-583
    • Rusthoven, K.E.1    Hammerman, S.F.2    Kavanagh, B.D.3    Birtwhistle, M.J.4    Stares, M.5    Camidge, D.R.6
  • 79
    • 84927167657 scopus 로고    scopus 로고
    • A Phase II trial of second-line erlontinib in combination with stereotactic body radiation therapy (SBRT) for patients with metastatic non-small cell lung cancer (NSCLC)
    • Iyengar P, Kavanagh B, Smith I, Ahn C, Gerber D, Dowell J, et. al. A Phase II trial of second-line erlontinib in combination with stereotactic body radiation therapy (SBRT) for patients with metastatic non-small cell lung cancer (NSCLC). J Clin Oncol. 2013;31:15 suppl:8074
    • (2013) J Clin Oncol. , vol.31 , Issue.15 SUPPL. , pp. 8074
    • Iyengar, P.1    Kavanagh, B.2    Smith, I.3    Ahn, C.4    Gerber, D.5    Dowell, J.6
  • 80
    • 84875936184 scopus 로고    scopus 로고
    • Harnessing the immune system for the treatment of non-small-cell lung cancer
    • J.R. Brahmer Harnessing the immune system for the treatment of non-small-cell lung cancer J Clin Oncol 31 2013 1021 1028
    • (2013) J Clin Oncol , vol.31 , pp. 1021-1028
    • Brahmer, J.R.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.